Regeneron Pharmaceuticals Inc (REGN)

595.40
+4.27(+0.72%)
After Hours
593.80
-1.60(-0.27%)
- Real-time Data
  • Volume:
    384,317
  • Day's Range:
    586.17 - 597.00
  • 52 wk Range:
    538.01 - 747.42

REGN Overview

Prev. Close
591.13
Day's Range
586.17-597
Revenue
16.51B
Open
587.76
52 wk Range
538.01-747.42
EPS
70.56
Volume
384,317
Market Cap
64.15B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
692,415
P/E Ratio
8.44
Beta
0.31
1-Year Change
2.01%
Shares Outstanding
107,746,194
Next Earnings Date
03 Aug 2022
What is your sentiment on Regeneron Pharma?
or
Market is currently closed. Voting is open during market hours.

Regeneron Pharmaceuticals Inc News

Regeneron Pharmaceuticals Inc Analysis

Regeneron Pharmaceuticals Inc Company Profile

Regeneron Pharmaceuticals Inc Company Profile

Employees
9766

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. It also provides Expresse service assurance and CloudCheck WiFi experience management solutions.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyBuyStrong SellBuy
Technical IndicatorsSellStrong BuyBuyBuyBuy
SummaryNeutralStrong BuyBuyNeutralBuy
  • Profit taking
    0
    • this is the worst stock I had ever invested in. it just keeps going down and down with no bottom in sight. what a disgrace.
      4
      • Me too
        0